Carbapenem resistance in Bacteroides fragilis: A review of molecular mechanisms.


Journal

Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 21 02 2022
revised: 10 06 2022
accepted: 16 06 2022
pubmed: 24 6 2022
medline: 14 9 2022
entrez: 23 6 2022
Statut: ppublish

Résumé

Carbapenems are an applicable subclass of β-lactam drugs in the antibiotic therapy of anaerobic infections, especially for poly-microbial cases, due to their broad antimicrobial spectrum on aerobic and anaerobic bacteria. Bacteroides fragilis is the most commonly recovered anaerobic bacteria in the clinical laboratories from mono- and poly-microbial infections. B. fragilis is relatively non-susceptible to different antibiotics, including β-lactams, tetracyclines, fluoroquinolones, and macrolides. Carbapenems are among the most effective drugs against B. fragilis strains with high-level resistance to different antibiotics. Increased antibiotic resistance of B. fragilis strains has been reported following the overuse of an antimicrobial agent. Earlier contact with carbapenems is linked with increased resistance to them that limits the options for treatment of B. fragilis caused infections, especially in cases caused by multidrug-resistant strains. Several molecular mechanisms of resistance to carbapenems have been described for different carbapenem-resistant bacteria. Understanding the mechanisms of resistance to antimicrobial agents is necessary for selecting alternative antimicrobial agents and the application of control strategies. In the present study, we reviewed the mechanisms contributing to resistance to carbapenems in B. fragilis strains.

Identifiants

pubmed: 35738484
pii: S1075-9964(22)00097-X
doi: 10.1016/j.anaerobe.2022.102606
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0
Carbapenems 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102606

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest There is no conflict of interest.

Auteurs

Mina Yekani (M)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.

Mohammad Ahangarzadeh Rezaee (MA)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Samad Beheshtirouy (S)

Cardiothoracic Department, Tabriz University of Medical Sciences, Tabriz, Iran.

Hossein Banazadeh Baghi (HB)

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Ahad Bazmani (A)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Abbas Farzinazar (A)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Yousef Memar (MY)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: memarm@tbzmed.ac.ir.

József Sóki (J)

Institute of Medical Microbiology, Albert Szent-Györgyi Health Centre and School of of Medicine, University of Szeged, Szeged, Hungary. Electronic address: soki.jozsef@med.u-szeged.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH